Unbelievable news for shareholders, this really puts the spot light on IMUGENE and so it should with all the incredible science and work being done behind the scenes.
Interestingly, the trial will be funded by IMU and will be trialling 'HER-Vaxx' in combination with chemo with or without 'Avelumab', in order to see whether there is any distinguishable difference. An unexpected result could be that Avelumab offers no better outcome for patients and in turn reflects poorly on Merck and Pfizer...
What I'm saying is that Merck and Pfizer are really putting their trust in the science and their reputation is on the line in collaborating with us. Remember that this is big pharma, and would leave no stone unturned in finding success and minimising risk where they can.
Merck and Pfizer are two of the top 5 biggest fish in the Big Pharma Sea.
What an opportunity for patients and shareholders.
GLTAH's
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-125
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
